1. Losartan vs. Atenolol in Marfan Syndrome
Trial design: Patients with Marfan syndrome were randomized to losartan (n = 70) vs. atenolol (n = 70). Maximum dose was 100 mg/day.
(p = 0.38)
Results
Change in aortic root diameter at 36 months: 1.1 mm in the losartan group vs. 1.4 mm in the atenolol group (p = 0.38)
Aortic events: One patient in the losartan group vs. four patients in the atenolol group (p = 0.38) mm
1.4
1.1
Conclusions
Among individuals with Marfan syndrome, losartan failed to prevent aortic root or ascending aorta dilatation compared with atenolol
Aortic events were similar between the groups
Losartan
Atenolol
Forteza A, et al. Eur Heart J 2015;Oct 29:[Epub]